Posted by Michael Wonder on 15 Dec 2022
Pembrolizumab for the neo-adjuvant and adjuvant treatment of patients with early or locally advanced triple negative breast cancer
14 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of pembrolizumab in the NHS in England.
Pembrolizumab is recommended as an option with chemotherapy for neo-adjuvant treatment and then continued alone as adjuvant treatment after surgery for adults with triple negative:
- Early breast cancer at high risk of recurrence or
- Locally advanced breast cancer
